J07CA06 • DTPA + IPV + HIB combination vaccine • Antiinfectives for systemic use | Bacterial and viral vaccines, combined
The combined DTPa+IPV+Hib vaccine is used for active immunization against diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, and infections caused by Haemophilus influenzae type B (Hib). This vaccine contains acellular components of Bordetella pertussis, diphtheria and tetanus toxoids, inactivated polioviruses, and the Hib capsular polysaccharide conjugated to a carrier protein.
The vaccine is administered intramuscularly, usually in multiple doses, according to recommended vaccination schedules for infants and young children. It is essential for preventing serious diseases such as poliomyelitis, meningitis, and epiglottitis, as well as complications associated with diphtheria, tetanus, and whooping cough.
Common side effects include fever, irritability, drowsiness, and pain at the injection site. In rare cases, severe allergic reactions may occur.
The combined DTPa+IPV+Hib vaccine is a crucial measure for protecting public health, helping to reduce the incidence of these infectious diseases and prevent severe complications associated with them.
Substance: DTPA + IPV + HIB combination vaccine
Date of last drug list: 01-01-2019
Commercial code: W13418016
Pharmaceutical form: powder + suspension for injection suspension
Quantity: 1
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: GLAXOSMITHKLINE BIOLOGICALS SA - BELGIA
Holder: GLAXOSMITHKLINE BIOLOGICALS SA - BELGIA
Number: 5880/2013/15
Shelf life: 3 years